#research

Microsoft unveiled two proprietary MAI models at Build, including a 1-trillion-parameter reasoning model and a 137B coding model for GitHub Copilot, as Uber hit its AI budget ceiling after burning through its full 2026 allocation in four months. Alnylam struck a $2 billion deal with Inceptive Nucleics to build AI foundation models for RNA interference therapeutics. Trump signed a narrower AI oversight executive order requiring a 30-day review before powerful open-weight models can be released. The Trump administration also moved to strip job protections from roughly 8,000 NIH staff, including officials who oversee research grants, while Medicaid work requirements drew criticism for going beyond what advocates had anticipated.

An OpenAI reasoning model disproved an 80-year-old Erdős conjecture in discrete geometry for under $1,000 in compute, a result mathematicians are calling one of the most significant AI contributions to pure math to date. Eli Lilly's retatrutide, a triple-receptor obesity drug, produced bariatric-surgery-level weight loss in a Phase 3 trial, though dropout rates from side effects were notable. Google shipped Gemini 3.5 Flash to general availability at Google I/O and announced a $100 AI Ultra subscription tier. The acting head of NIH's infectious disease institute stepped down as senators pressed NIH Director Jay Bhattacharya on leadership gaps and a proposed 2027 budget cut. Kevin Warsh was confirmed and sworn in as the new Federal Reserve chair this week.

The FDA's leadership vacuum deepened this week as the drug center head followed Commissioner Makary out the door, leaving the agency with no confirmed leadership at its two most critical posts. Open-weight models kept multiplying with Gemma 4, DeepSeek V4, and Kimi K2.6 all dropping in the same month, while Sebastian Raschka's analysis of new KV-sharing and compressed attention techniques explains why long-context costs are falling fast. A rare Bundibugyo Ebola outbreak in Congo's Ituri province prompted a WHO public health emergency declaration, and the WHO's move landed as hantavirus conspiracy theories were already cycling through social media. On the economy side, Trump's China visit produced mixed signals on decoupling, while Noah Smith argued that Europe's comfortable stagnation is no longer viable.

Sebastian Raschka published a comprehensive 2025 LLM review covering DeepSeek R1, RLVR, inference-time scaling, and 2026 predictions, while Simon Willison released his annual year-in-LLMs retrospective. On the pharma front, NIH Director Jay Bhattacharya confirmed that DEI-related grants restored under a court order will not be renewed in 2026, even as NIH began reviewing thousands of delayed proposals and funded 135 on the first day. Novo Nordisk priced its newly approved Wegovy pill below Eli Lilly's competing obesity drug in a direct-to-consumer push. On the economy side, researchers across 16 countries found that the post-1980 labor share decline is driven by the composition of capital, not its quantity, and building more structures may reverse it.